Sign In to Request a Protocol
Sign In to Request a Protocol

Adipotide (10 mg Vial) Dosage Protocol

  • Table of Contents

Adipotide Dosage Chart

Adipotide is dosed at 250 mcg–1 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
  • Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration.
  • Starting dose: 250 mcg once daily; gradual escalation by 250 mcg every 2 weeks as tolerated.
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro‑apoptotic sequence to destroy those vessels, resulting in targeted fat mass reduction as fat cells lose their blood supply. Preclinical studies showed notable weight loss in obese rodents and primates; however, clinical development was discontinued after a Phase 1 trial due to safety concerns. This educational protocol presents a cautious once‑daily subcutaneous titration approach with careful dose escalation.
  • Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

PhaseDaily Dose (mg)Units (per injection) (mL)
Weeks 1–2250 mcg7.5 units (0.08 mL)
Weeks 3–4500 mcg15 units (0.15 mL)
Weeks 5–6750 mcg22.5 units (0.23 mL)
Weeks 7–81000 mcg (1.0 mg)30 units (0.30 mL)
 Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) and starts at a conservative dose with gradual escalation to mitigate potential renal side effects observed at higher doses in preclinical studies. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption. Clinical development was discontinued due to safety concerns.
  • Supplies Needed
Plan based on an 8–week cautious titration protocol with once‑daily administration.
  • Peptide Vials (Adipotide, 10 mg each):
  • 8 weeks ≈ 4 vials
  • 12 weeks ≈ 7 vials
  • 16 weeks ≈ 10 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
  • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview
Concise summary of the once‑daily regimen.
  • Goal: Targeted reduction of fat mass via vascular targeting in adipose tissue.
  • Schedule: Daily subcutaneous injections for 4–8 weeks (cautious approach due to limited human data).
  • Dose Range: 250–1000 mcg daily with gradual titration every 2 weeks.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Dosing Protocol

Suggested approach for the 50 mg vial format.

  • Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated
  • Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated)
  • Frequency: Once per day (subcutaneous).
  • Cycle Length:: 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
  • Timing: Any consistent time; rotate injection sites systematically.
  • Storage Instructions
Proper storage preserves peptide quality.
  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher doses. This protocol is for educational purposes only.
  • How This Works
Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment. A first‑in‑human Phase 1 trial was initiated in obese cancer patients, but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher doses.
  • Potential Benefits & Side Effects
Observations from preclinical literature and limited human data.
  • Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)
  • Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models
  • Safety concerns: Clinical development was discontinued due to safety issues; reversible kidney toxicity was dose‑dependent in preclinical studies.
  • Mild injection‑site reactions (redness, swelling) may occur with subcutaneous administration.
  • Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.
  • Lifestyle Factors
Complementary strategies for best outcomes.
  • Pair with a balanced, protein‑forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize sleep and stress management to support adherence and recovery.
  • Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.
  • Injection Technique
General subcutaneous guidance from clinical best‑practice resources
  • Clean the vial stopper and skin with alcohol; allow to dry fully.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue)
  • Do not aspirate for subcutaneous injections; inject slowly and steadily
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
  • Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.
  • Recommended Source

We recommend Vitality Labs Peptides for high‑purity Adipotide (10 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Adipotide’s clinical development was discontinued due to safety concerns. This information is for research purposes only. Not for human consumption.
  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

Science Translational Medicine (PubMed)

— A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

More Info

MD Anderson Cancer Center

— Obese Monkeys Lose Weight on Drug that Attacks Blood Supply of Fat Cells

More Info

Arrowhead Pharmaceuticals News

— Dosing of First Patient with Anti-Obesity Treatment Adipotide in a Phase 1 Clinical Trial

More Info

Cardiovascular Diabetology (PMC)

— Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT)

More Info

Bachem Technical Note

— Care and Handling of Peptides
More Info

BC Open Textbook Project

— 7.3 Intradermal and Subcutaneous Injections – Clinical Procedures for Safer Patient Care
More Info

Immunize.org (IAC)

— Ask the Experts: Administering Vaccines – General Issues (no aspiration guidance)
More Info

Los Angeles Times

— Cancer treatment shows promise for rapid weight loss

More Info

ScienceDaily

— Obese monkeys lose weight on drug that attacks blood supply of fat cells

More Info

CDC

— Vaccine administration: subcutaneous route guidance
More Info

CDC (Subcut Injection PDF)

— Technique diagram and site guidance for subcutaneous injections

More Info

NCBI Bookshelf

— Best practices for injection (asepsis, preparation, and administration)
More Info

Subcutaneous Drug Injection Review (PMC)

— Pharmacologic considerations of the subcutaneous route
More Info

Vitality Lab Peptides

— Adipotide (10 mg) product page (quality and batch documentation) View Source
More Info